TY - JOUR
T1 - Effect of bright light therapy on cancer-related fatigue and related symptoms
T2 - A systematic review and meta-analysis of randomized controlled trials
AU - Lin, Lee Yuan
AU - Tam, Ka Wai
AU - Huang, Tsai Wei
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/11
Y1 - 2023/11
N2 - Objective: Cancer-related fatigue (CRF) is a common side effect in cancer patients, possibly due to disrupted circadian rhythms. While bright light therapy (BLT) is known to modulate circadian rhythms, its role in mitigating CRF remains unclear. This study examined the impact of BLT on CRF and other related symptoms. Methods: PubMed, Embase, Cochrane Library, and SCOPUS databases were searched. The trials were selected according to the PRISMA guidelines. The severity and quality of CRF and related symptoms were investigated in post-BLT intervention. Results: Twelve trials involving 691 were included. BLT significantly reduced CRF (SMD = −0.92, 95% CI: −1.45 to −0.40, p < 0.00001, I2 = 90%) and insomnia (SMD = −2.80, 95% CI: −4.61 to −0.98, I2 = 0%). Subgroup analyzes were performed based on various factors including light illuminance and intervention duration. BLT was found to be effective in both preventing and treating CRF, though it did not significantly enhance sleep quality, depression, and quality of life (QoL). Conclusion: BLT is a promising intervention for managing CRF in cancer patients. Its efficacy in improving sleep quality, and insomnia, reducing depression, and enhancing QoL requires further exploration. A 4-week BLT intervention with ≥10,000 lx is recommended for preventing and treating CRF, with longer or less intense interventions also showing effectiveness. Otherwise, BLT exhibited minimal adverse effects.
AB - Objective: Cancer-related fatigue (CRF) is a common side effect in cancer patients, possibly due to disrupted circadian rhythms. While bright light therapy (BLT) is known to modulate circadian rhythms, its role in mitigating CRF remains unclear. This study examined the impact of BLT on CRF and other related symptoms. Methods: PubMed, Embase, Cochrane Library, and SCOPUS databases were searched. The trials were selected according to the PRISMA guidelines. The severity and quality of CRF and related symptoms were investigated in post-BLT intervention. Results: Twelve trials involving 691 were included. BLT significantly reduced CRF (SMD = −0.92, 95% CI: −1.45 to −0.40, p < 0.00001, I2 = 90%) and insomnia (SMD = −2.80, 95% CI: −4.61 to −0.98, I2 = 0%). Subgroup analyzes were performed based on various factors including light illuminance and intervention duration. BLT was found to be effective in both preventing and treating CRF, though it did not significantly enhance sleep quality, depression, and quality of life (QoL). Conclusion: BLT is a promising intervention for managing CRF in cancer patients. Its efficacy in improving sleep quality, and insomnia, reducing depression, and enhancing QoL requires further exploration. A 4-week BLT intervention with ≥10,000 lx is recommended for preventing and treating CRF, with longer or less intense interventions also showing effectiveness. Otherwise, BLT exhibited minimal adverse effects.
KW - Bright light therapy
KW - cancer-related fatigue
KW - Depression
KW - Insomnia
KW - Sleep quality
UR - http://www.scopus.com/inward/record.url?scp=85173024921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85173024921&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychores.2023.111501
DO - 10.1016/j.jpsychores.2023.111501
M3 - Article
C2 - 37797569
AN - SCOPUS:85173024921
SN - 0022-3999
VL - 174
JO - Journal of Psychosomatic Research
JF - Journal of Psychosomatic Research
M1 - 111501
ER -
